SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

Lite Strategy, Inc. (NASDAQ:LITS)

US · Delayed Price · Currency is USD
1.44+0.01 (+0.70%)
 
Market Cap49.00M-43.3%
Revenue (ttm)0
Net Income-60.82M-92.1%
EPS-1.79-92.2%
Shares Out34.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateNov 16, 2023
Volume2,261,682
Open1.43
Previous Close1.43
Day's Range1.36 - 1.53
52-Week Range0.69 - 2.97
Beta0.04
Analystsn/a
Price Targetn/a
Earnings DateSep 28, 2026
Insider Score
––Not scored
LITS Insider Score

No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.

About LITS

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Address
9920 Pacific Heights Blvd., San Diego, CA, 92121, US
Market Cap
49 million
Employees
4
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$946.14K
Bought
$141.86K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+0.70%
5 Days
+34.58%
1 Month
+37.14%
6 Months
+20.00%
1 Year
-43.31%

$LITS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LITS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LITS's directors and management

Net Shares Purchased by Insiders−700k−350k02025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LITS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LITS Revenue by Segment

$8.91MTotal
SegmentRevenue% of All
Cash and cash equivalents$7.54M84.66%
Asset management fee and advisory fees$675.00K7.57%
Professional fees$409.00K4.59%
Legal fees$283.00K3.18%

As of: Q1 2026 (Mar 31, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LITS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LITS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LITS

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$650.37K
VXFVanguard Extended Market ETF$356.71K
IWCiShares Micro-Cap ETF$155.02K

Estimated from each fund’s disclosed top holdings × AUM

LITS Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for LITS yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from LITS’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
3
Sells
1
Buy Value
$141.86K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
Company Directory & Stock Ticker Database | InsiderBuying.com